Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Phase 2

Withdrawn

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions: Biological: Tisagenlecleucel

First Posted Date: 2020-07-02

Last Posted Date: 2022-03-02

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04456023

A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Dabrafenib
Drug: Trametinib

First Posted Date: 2020-07-01

Last Posted Date: 2025-02-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT04452877

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)

Phase 1

Terminated

Conditions: Sickle Cell Disease

Interventions: Biological: OTQ923

First Posted Date: 2020-06-23

Last Posted Date: 2025-02-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT04443907

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
🇺🇸
St Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Phase 3

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Capmatinib
Drug: Docetaxel

First Posted Date: 2020-06-11

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 22

Registration Number: NCT04427072

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Ribociclib
Drug: Trametinib
Drug: LXH254
Drug: LTT462

First Posted Date: 2020-06-04

Last Posted Date: 2025-04-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 134

Registration Number: NCT04417621

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 9 locations

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: CSJ117
Drug: Placebo

First Posted Date: 2020-06-01

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 335

Registration Number: NCT04410523

Locations: 🇸🇰
Novartis Investigative Site, Presov, Slovakia

The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.

Phase 1

Completed

Conditions: Liver Disease

Interventions: Drug: triopifexor
Drug: Placebo

First Posted Date: 2020-05-29

Last Posted Date: 2022-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 89

Registration Number: NCT04408937

Locations: 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

Phase 2

Terminated

Conditions: Bronchiectasis

Interventions: Drug: QBW251
Drug: Placebo

First Posted Date: 2020-05-20

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT04396366

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Phase 2

Terminated

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Biological: NIS793
Biological: Spartalizumab
Drug: gemcitabine
Drug: nab-paclitaxel

First Posted Date: 2020-05-18

Last Posted Date: 2025-05-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 164

Registration Number: NCT04390763

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Univ of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 3 locations

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Phase 2

Completed

Conditions: Dry Eye

Interventions: Other: ECF843 vehicle
Drug: ECF843

First Posted Date: 2020-05-18

Last Posted Date: 2025-01-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 718

Registration Number: NCT04391894

Locations: 🇺🇸
Arizona Eye Center, Chandler, Arizona, United States
🇺🇸
Carrot Eye Center, Mesa, Arizona, United States
🇺🇸
Lee Shettle Eye & Hearing, Largo, Florida, United States

and more 49 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy